Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P17787

UPID:
ACHB2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P17787; Q9UEH9

BACKGROUND:
The protein Neuronal acetylcholine receptor subunit beta-2, with the unique identifier P17787, is crucial for the activation of acetylcholine receptors. These receptors respond to the neurotransmitter acetylcholine by opening an ion channel that allows sodium ions to pass through, facilitating neuronal communication.

THERAPEUTIC SIGNIFICANCE:
This protein's mutation is associated with Epilepsy, nocturnal frontal lobe, 3, characterized by specific nocturnal seizures. The direct link between Neuronal acetylcholine receptor subunit beta-2 and this form of epilepsy highlights its therapeutic relevance, suggesting that further research could lead to novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.